Navigation Links
ITMN in Medical News

Important Data Presented on Independent Predictors of Mortality in Patients With Idiopathic Pulmonary Fibrosis

...orced Vital Capacity is among strongest predictors of one-year mortality - SAN DIEGO, May 17 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today reported that results of a study assessing the relationship between various measures of clinical status and the risk of death in patients with...

InterMune to Present at Cowen Health Care Conference

... BRISBANE, Calif., March 13 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Cowen and Company 29th Annua...

InterMune Reports Results from Triple Combination Study of ITMN-191

...gin in Q2 2009 - - Conference call today at 8:30 a.m. EST - BRISBANE, Calif., Jan. 12 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today reported top-line results from all six completed dosage cohorts of its Phase 1b clinical trial of ITMN-191 (R7227) in combination with standar...

InterMune to Present at Thomas Weisel Partners Healthcare Conference

... BRISBANE, Calif., Aug. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the Thomas Weisel Partners Healthcare Conference in ...

InterMune to Present at the 2008 Wachovia Healthcare Conference

... BRISBANE, Calif., Jan. 23 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Steven Porter, M.D., Ph.D., Chief Medical Officer of InterMune, will present at the 2008 Wachovia Healthcare Conference in Bost...

HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...ics Inc RESP 157248157.2 Theravance Inc THRX 212837798.5 Intermune Inc itmn 296874543.2 Sepracor Inc. SEPR 385036542.3 Nektar Therapeutics NKTR 1272671080 Encys...
ITMN in Medical Technology

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

...eported - - Conference Call and Webcast at 9 p.m. EDT (6 p.m. PDT) - SAN DIEGO, May 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) reported that results from the two Phase 3 CAPACITY studies evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) were present...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

...nts with hepatitis C - NUTLEY, N.J., BRISBANE, Calif., and PRINCETON, N.J., April 25 /PRNewswire-FirstCall/ -- Roche, InterMune, Inc. (Nasdaq: itmn ) and Pharmasset (Nasdaq: VRUS ) today announced the first results from their innovative, interferon-free regimen of direct acting antiviral (DAA) c...

InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)

...dy - -- Phase 2b program anticipated to begin in summer 2009 -- COPENHAGEN , April 24 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that results from a 14-day Phase 1b clinical study of ITMN-191 (R7227) in combination with the current standard of care were present...

InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3

... BRISBANE, Calif., Feb. 2 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that it will report results from its Phase 3 CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis (IPF) prior to market ...

InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191

... BRISBANE, Calif., Jan. 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that it will conduct a conference call and webcast on Monday, January 12 at 8:30 a.m. EST to discuss results from its Phase 1b, 14-d...

InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009

... BRISBANE, Calif., Dec. 10 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today said that it will report top-line results in January 2009 from its Phase 1b clinical trial of protease inhibitor ITMN-191 (R7227) in combinati...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C

... PRINCETON, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ), Roche (SWX: ROG) and InterMune, Inc. (Nasdaq: itmn ) today announced that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus ...

InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C

...nued development in treatment-experienced patients - BRISBANE, Calif., May 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that it has begun dosing in its Phase 1b clinical trial evaluating ITMN-191, designated R7227 at Roche (SWX: ROG), in combination wi...

InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA

...s Shionogi Phase 3 results on pirfenidone - BRISBANE, Calif., May 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that its program for the development of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) has received "Fast Trac...

InterMune Announces Progress on Pirfenidone in IPF

...ne study now available on ATS website - BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that it will initiate an open-label roll-over study to evaluate the long-term safety of pirfenidone in patients with idiopathic pulm...
ITMN in Biological Technology

InterMune to Present at Canaccord Adams Conference

... BRISBANE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Canaccord Adams 29th Annual Global...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

... BRISBANE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced results from operations for the second quarter and six months ended June 30, 2009. InterMune reported a net loss for the second q...

InterMune to Release Second Quarter Financial Results on August 6

... BRISBANE, Calif., July 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) announced today that it will release second quarter 2009 financial results on Thursday, August 6, 2009 at 4:00 p.m. Eastern time. A live conference...

InterMune to Present at Goldman Sachs Healthcare Conference

... BRISBANE, Calif., June 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Daniel Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Goldman Sachs 30th Annual Globa...

Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS

... - Conference call and webcast Tuesday, May 19, 6 p.m. PDT - BRISBANE, Calif., May 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that an oral late-breaker presentation and two poster discussion presentations related to the company's pulmonology programs will be...

InterMune Reports First Quarter 2009 Financial Results and Business Highlights

... data from 14-day triple combination study of ITMN-191 in HCV - BRISBANE, Calif. , April 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced results from operations for the first quarter ended March 31, 2009. InterMune reported a net loss for the first quarter of 2009 o...

INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients

... - Twice-Daily Dosing and Higher Doses of ITMN-191 (R7227) - BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that the innovative clinical study of protease inhibitor ITMN-191 (R7227) in combination with nucleoside polymerase inhibitor R7128 ...

InterMune to Release First Quarter Financial Results on April 30

... BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) announced today that it will release first quarter 2009 financial results on Thursday, April 30, 2009 at 4:00 p.m. Eastern time. A live conference ...

InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25

... -- Conference Call and Webcast Scheduled -- BRISBANE, Calif., April 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that InterMune and Pharmasset, Inc. will host a live webcast of a discussion of the INFORM-1 results from the EASL conference on Sat...

InterMune to Present at Canaccord Adams Hepatitis C Conference

... BRISBANE, Calif., April 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: itmn ) today announced that Steven B. Porter, M.D., Ph.D., Chief Medical Officer of InterMune, will present at the Canaccord Adams Hepatitis C Conference o...
Other Tags
(Date:7/12/2014)... Using and carrying around a catheter ... from Ashland, Va., decided that there needed to be ... to conceive of our design," he said. , They ... which provides an inconspicuous way to use and carry ... as promotes comfort and peace of mind. Producible in ...
(Date:7/12/2014)... July 12, 2014 “Critical Care ... New and Late-Stage Four-Factor PCCs and Recombinant Products ... the critical care market in the US, UK, ... report provides an estimation of market size for ... covers critical care indications that are being treated ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 A recent article ... provides a trio of suggestions for those seeking cosmetic ... days are rapidly approaching and the heat begins to enliven ... to their summer clothing, realizing that they didn’t work out ... , This can cause a sudden surge of people eager ...
(Date:7/12/2014)... Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
(Date:7/11/2014)... July 11, 2014 The American Association ... 55 poison centers are commending Senator Bill Nelson (D-FL) ... Act of 2014 on July 10, 2014. Along with ... Products Safety Commission (CPSC) to enact rules requiring safer, ... , Senate co-sponsors of the bill include: ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3
(Date:7/11/2014)... to study the proteins that let nerve cells send ... stumbled upon a biological tactic that may offer a ... a safe and environmentally responsible way. , Their ... one species and harmless for a closely related onesuggests ... without harming beneficial species like bees. A summary of ...
(Date:7/10/2014)... Fe, Albuquerque, and other major cities in New Mexico, ... treated municipal wastewater rather than precious potable water supplies. ... 40% of all golf courses receive treated effluent. Reusing ... , Additionally, golf courses and homeowners alike fertilize their ... fertilizer is nitrate. A New Mexico State University turfgrass ...
(Date:7/10/2014)... , June 27, 2014  Pomerantz LLP ... Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and ... in United States District Court, Middle District of ... on behalf of a class consisting of all ... Provectus securities between December 17, 2013 and May ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3'Tailored' water -- the latest in lawn care 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
Other Contents